Zhitong Finance App News, Hanyu Pharmaceutical (300199.SZ) issued an announcement. The company recently received a notice from the US Food and Drug Administration (FDA) to accept the clinical trial application for HY3003 injection.

HY3003 is a GLP-1R/GIPR/GCGR three-target receptor agonist selected using AI polypeptide chip technology. It is intended for use in indications such as weight loss, type 2 diabetes, and metabolism-related fatty hepatitis. It is a major innovative drug type in the company's layout in the field of metabolic diseases. The HY3003 project uses a multi-dosage parallel development strategy. The development direction includes HY3003 injection (weekly formulation), HY3003 extended-release injection (monthly formulation), and HY3003 tablets (once-daily oral formulation).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.